{
  "source": "PA-Notification-Rezdiffra.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1443-2\nProgram Prior Authorization/Notification\nMedication Rezdiffra™ (resmetirom)\nP&T Approval Date 4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nRezdiffra™ (resmetirom) is a thyroid hormone receptor-beta (THR-beta) agonist indicated in\nconjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic\nsteatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to\nF3 fibrosis). This indication is approved under accelerated approval based on improvement of\nNASH and fibrosis. Continued approval for this indication may be contingent upon\nverification and description of clinical benefit in confirmatory trials.\nLimitations of Use:\nAvoid use of Rezdiffra in patients with decompensated cirrhosis.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Rezdiffra will be approved based on both of the following criteria:\na. Diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) [formerly\nknown as nonalcoholic steatohepatitis (NASH)]\n-AND-\nb. Moderate to advanced liver fibrosis (i.e., fibrosis stage F2 or F3)\nAuthorization will be issued for 12 months\nB. Reauthorization\n1. Rezdiffra will be approved based on the following criterion:\na. Documentation of positive clinical response to Rezdiffra therapy\nAuthorization will be issued for 12 months\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits, Medical Necess",
    " claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits, Medical Necessity and/or Step Therapy may be in place.\n4. References:\n1. Rezdiffra [package insert]. West Conshohocken, PA: Madrigal Pharmaceuticals, Inc.;\nMarch 2024.\nProgram Prior Authorization/Notification – Rezdiffra (resmetirom)\nChange Control\n4/2024 New program.\n4/2025 Annual review with no changes to criteria.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}